Carrelizumab Combined With Concurrent Radiotherapy and Chemotherapy for Unresectable Esophageal Squamous Cell Carcinoma
Condition: Esophageal Squamous Cell Carcinoma Interventions: Drug: Carrelizumab; Drug: Paclitaxel injection; Drug: Cisplatin; Radiation: Concurrent chemoradiotherapy Sponsor: The First Affiliated Hospital with Nanjing Medical University Enrolling by invitation
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer & Oncology | Carcinoma | Chemotherapy | Esophagus Cancer | Hospitals | Research | Skin Cancer | Squamous Cell Carcinoma